Agilent delivered another resilient quarter, underscoring the strength of its diversified end-market portfolio and the effectiveness of its Ignite operating system. In Q4 2025, revenue reached $1.86 billion, with core revenue growth of 7.2% and a margin expansion that reflects improved operating leverage and tariff mitigation. Management framed the year as a transition into FY26, emphasizing continued investment in high-return growth engines (Infinity 3/Pro IQ LCMS, Alturo BioInert columns, and GLP-1 CDMO capabilities via BioVectra), alongside a modernization of go-to-market capabilities through AI-enabled CRM and elevated pricing strategy. The company then provided a cautious, yet constructive, FY26 guidance of 4%–6% core revenue growth, 75 basis points of midyear operating margin expansion, and non-GAAP EPS of $5.86–$6.00, with FCF guidance of $1.6–$1.7 billion. Management positions Agilent’s Ignite program as the primary accelerator of earnings power, aided by a robust balance sheet (net leverage ~0.8x) that supports strategic capacity expansion and M&A opportunities, including the BioVectra integration which is now a structural part of the platform. The tone from leadership emphasizes continued innovation, disciplined capital allocation, and a favorable long‑term growth runway in pharma/biotech, diagnostics, and environmental/forensics applications. Overall, the setup suggests solid, above‑peer growth with improving margins into FY26, supported by a diversified end-market mix and a recurring services/consumables component.